AP
MRK icon

Antipodes Partners’s Merck MRK Stock Holding History

Antipodes Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141M Sell
1,097,509
-343,757
-24% -$40.2M 2.58% 11
2026
Q1 		$173M Sell
1,441,266
-134,545
-9% -$15.5M 3.34% 5
2025
Q4 		$166M Sell
1,575,811
-95,741
-6% -$8.99M 3.48% 6
2025
Q3 		$140M Sell
1,671,552
-142,708
-8% -$11.8M 3.15% 12
2025
Q2 		$144M Sell
1,814,260
-153,710
-8% -$12.2M 4.45% 7
2025
Q1 		$177M Buy
1,967,970
+119,339
+6% +$11.1M 5.53% 5
2024
Q4 		$184M Buy
1,848,631
+272,815
+17% +$28.1M 6.39% 4
2024
Q3 		$179M Sell
1,575,816
-99,830
-6% -$11.9M 6.2% 3
2024
Q2 		$207M Sell
1,675,646
-213,659
-11% -$27.5M 7.54% 1
2024
Q1 		$249M Sell
1,889,305
-285,599
-13% -$35.2M 7.88% 1
2023
Q4 		$237M Sell
2,174,904
-95,095
-4% -$9.87M 7.41% 1
2023
Q3 		$237M Buy
2,269,999
+520,841
+30% +$56.1M 7.61% 1
2023
Q2 		$202M Sell
1,749,158
-107,402
-6% -$12.2M 6.97% 1
2023
Q1 		$198M Buy
1,856,560
+1,121
+0.1% +$121K 6.85% 1
2022
Q4 		$206M Sell
1,855,439
-409,457
-18% -$41.9M 7.38% 1
2022
Q3 		$195M Buy
2,264,896
+316,431
+16% +$28.2M 7.83% 1
2022
Q2 		$178M Sell
1,948,465
-239,177
-11% -$21.2M 7.4% 1
2022
Q1 		$179M Buy
2,187,642
+222,174
+11% +$17.5M 6.36% 2
2021
Q4 		$151M Buy
1,965,468
+62,956
+3% +$5.01M 5.41% 7
2021
Q3 		$143M Sell
1,902,512
-154,947
-8% -$11.8M 4.88% 6
2021
Q2 		$160M Sell
2,057,459
-72,933
-3% -$5.42M 5.77% 3
2021
Q1 		$157M Buy
2,130,392
+108,406
+5% +$8M 6.35% 3
2020
Q4 		$158M Buy
2,021,986
+202,783
+11% +$15.5M 6.86% 3
2020
Q3 		$144M Sell
1,819,203
-161,405
-8% -$12.6M 6.6% 4
2020
Q2 		$146M Buy
1,980,608
+39,093
+2% +$2.94M 6.62% 3
2020
Q1 		$143M Buy
+1,941,515
New +$153M 7.46% 3
2019
Q4 		– Sell
-1,853,247
Closed -$149M – 33
2019
Q3 		$149M Buy
1,853,247
+317,954
+21% +$25.5M 7.1% 3
2019
Q2 		$123M Buy
+1,535,293
New +$118M 5.64% 8

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Antipodes Partners's MRK Position: Q2 2026 in Review

Antipodes Partners reduced its Merck (MRK) stake by 24% in Q2 2026, selling an estimated $40.2M and leaving 1,097,509 shares worth $141M. The position accounts for 2.58% of the portfolio, ranked #11.

Antipodes Partners first reported a position in MRK in Q2 2019 and has held it in 28 quarters since. The position peaked at $249M in Q1 2024. 3,844 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Antipodes Partners held 1,097,509 shares of Merck worth $141M as of Q2 2026.
  • Antipodes Partners sold 343,757 Merck shares in Q2 2026, an estimated $40.2M.
  • Merck made up 2.58% of Antipodes Partners's portfolio in Q2 2026, its #11 holding.
  • Antipodes Partners first reported a position in Merck in Q2 2019 and has held it in 28 quarters since.
  • Antipodes Partners's Merck position peaked at $249M in Q1 2024.
  • 3,844 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.